Allogene Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Allogene Therapeutics, Inc. (ALLO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $532.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-03-12
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-03-31 was $532.00K, a 11.77% decline year-over-year.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-09-30 was $432.00K, a 0.00% change year-over-year.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-06-30 was $432.00K, a 46.86% decline year-over-year.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $603.00K, a 50.90% decline year-over-year.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $532.00K, a 73.39% decline from fiscal 2023.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $2.00M, a 31.19% decline from fiscal 2022.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $2.90M, a 24.51% decline from fiscal 2021.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $3.85M, a 35.49% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2024-12-31 | $532.00K 10-K · filed 2026-03-12 | |||
| 2024-03-31 | $532.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $2.00M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $432.00K 10-Q · filed 2024-11-07 | $864.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.47M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $432.00K 10-Q · filed 2024-11-07 | $1.03M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $603.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $2.90M 10-K/A · filed 2024-03-14 | |||
| 2022-09-30 | $432.00K 10-Q · filed 2023-11-02 | $1.25M derived: sum of 2 quarters · filed 2023-11-02 | $2.47M derived: sum of 3 quarters · filed 2023-11-02 | $3.62M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $813.00K 10-Q · filed 2023-11-02 | $2.04M 10-Q · filed 2022-08-09 | $3.18M derived: sum of 3 quarters · filed 2024-03-14 | $4.33M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $1.23M 10-Q · filed 2023-11-02 | $2.37M derived: sum of 2 quarters · filed 2024-03-14 | $3.51M derived: sum of 3 quarters · filed 2024-03-14 | $4.37M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $1.14M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $2.28M derived: sum of 2 quarters · filed 2024-03-14 | $3.14M derived: sum of 3 quarters · filed 2024-03-14 | $3.85M 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $1.14M 10-Q · filed 2022-11-02 | $2.00M derived: sum of 2 quarters · filed 2022-11-02 | $2.71M 10-Q · filed 2021-11-04 | $3.42M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-06-30 | $854.00K 10-Q · filed 2022-11-02 | $1.56M 10-Q · filed 2022-08-09 | $2.27M derived: sum of 3 quarters · filed 2024-03-14 | $2.98M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-03-31 | $710.00K 10-Q · filed 2022-11-02 | $1.42M derived: sum of 2 quarters · filed 2024-03-14 | $2.13M derived: sum of 3 quarters · filed 2024-03-14 | $2.84M derived: sum of 4 quarters · filed 2024-03-14 |
| 2020-12-31 | $710.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $1.42M derived: sum of 2 quarters · filed 2024-03-14 | $2.13M derived: sum of 3 quarters · filed 2024-03-14 | $2.84M 10-K/A · filed 2024-03-14 |
| 2020-09-30 | $710.00K 10-Q · filed 2021-11-04 | $1.42M derived: sum of 2 quarters · filed 2021-11-04 | $2.13M 10-Q · filed 2021-11-04 | $2.84M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $710.00K 10-Q · filed 2021-08-04 | $1.42M 10-Q · filed 2021-08-04 | $2.13M derived: sum of 3 quarters · filed 2022-02-23 | $2.84M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $710.00K 10-Q · filed 2021-05-05 | $1.42M derived: sum of 2 quarters · filed 2022-02-23 | $2.13M derived: sum of 3 quarters · filed 2022-02-23 | $5.30M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $710.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $1.42M derived: sum of 2 quarters · filed 2022-02-23 | $4.59M derived: sum of 3 quarters · filed 2022-02-23 | $4.59M 10-K · filed 2022-02-23 |
| 2019-09-30 | $710.00K 10-Q · filed 2020-11-04 | $3.88M derived: sum of 2 quarters · filed 2020-11-04 | $3.88M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $3.17M 10-Q · filed 2020-08-05 | $3.17M 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |